Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities.

Burcu Aslan CandirTuğçe Nur YiğenoğluMerih Kızıl Çakar Mehmet Sinan DalFevzi Altuntaş

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

Serious adverse events of ibrutinib are seen when treating CLL patients. This group of individuals should be closely monitored for potentially serious complications such as pericardial effusion and cardiac tamponade.

Keyphrases

chronic lymphocytic leukemia
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
left ventricular
peritoneal dialysis
case report
heart failure
risk factors
patient reported outcomes
atrial fibrillation